Bibliographic information
Recommendation
The World Health Organisation (WHO) suggest not to use ruxolitinib or tofacitinib for patients with severe or critical COVID-19
Recommended against
Conditional
Certainty of evidence
Very low
Notes and Remarks
Practical Info Route, dosage and duration: We refer to the table of trial characteristics (ruxolitinib and tofacitinib) to guide the administration of these agents, in the absence of other available information. Timing: Ruxolitinib or tofacitinib (like IL-6 receptor blockers) should be initiated with systemic corticosteroids; specific timing during hospitalization or the course of illness is not specified.
Also Featured In
This recommendation also appears in the following guidelines:
Therapeutics and COVID-19: living guideline, 14 January 2022.
Therapeutics and COVID-19: living guideline, 3 March 2022.
Therapeutics and COVID-19: living guideline, 22 April 2022.
Therapeutics and COVID-19: living guideline, 14 July 2022.
Therapeutics and COVID-19: living guideline, 13 January 2023.
Therapeutics and COVID-19: living guideline, 10 November 2023.
Therapeutics and COVID-19: living guideline, August 2025